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Introduction
Aminoglycoside antibiotics offer an effective treatment against life-threatening infections, including 
sepsis and tuberculosis (1, 2). They do, however, cause dose-related nephro- and ototoxicity (3, 4). 
Whereas damage to the kidneys is reversible (5), some degree of  permanent hearing loss has been 
reported in approximately 20% of  patients treated with aminoglycosides (6, 7). Vestibular dysfunction 
is also not uncommon and may even be more frequent (8, 9). The clinical use of  these antibiotics will 
continue until further drugs are developed that are affordably priced, available worldwide, and equally 
effective against infections currently treated with aminoglycosides. Finding methods to prevent the 
associated hearing loss is therefore critical.
Most attempts to identify compounds that could be coadministered with aminoglycosides to pro-
vide otoprotection without diminishing bactericidal activity have focused on testing antioxidants and 
antiapoptotic agents (10–19). Other attempts have screened libraries of  FDA-approved drugs (20) or 
libraries of  molecules that interact with ion channels (21). Thus far, there has been only 1 unbiased 
screen of  a moderately large and diverse chemical library (22), a study in which 10,960 compounds 
in the Chembridge Diverse E set were screened at 10 μM for ability to protect zebrafish lateral-line 
hair cells against short-term exposure to a high concentration of  neomycin (200 μM). This screen 
identified 2 compounds, PROTO-1 and PROTO-2, both of  which protected extrastriolar hair cells in 
To identify small molecules that shield mammalian sensory hair cells from the ototoxic 
side effects of aminoglycoside antibiotics, 10,240 compounds were initially screened in 
zebrafish larvae, selecting for those that protected lateral-line hair cells against neomycin and 
gentamicin. When the 64 hits from this screen were retested in mouse cochlear cultures, 8 
protected outer hair cells (OHCs) from gentamicin in vitro without causing hair-bundle damage. 
These 8 hits shared structural features and blocked, to varying degrees, the OHC’s mechano-
electrical transducer (MET) channel, a route of aminoglycoside entry into hair cells. Further 
characterization of one of the strongest MET channel blockers, UoS-7692, revealed it additionally 
protected against kanamycin and tobramycin and did not abrogate the bactericidal activity of 
gentamicin. UoS-7692 behaved, like the aminoglycosides, as a permeant blocker of the MET 
channel; significantly reduced gentamicin–Texas red loading into OHCs; and preserved lateral-line 
function in neomycin-treated zebrafish. Transtympanic injection of UoS-7692 protected mouse 
OHCs from furosemide/kanamycin exposure in vivo and partially preserved hearing. The results 
confirmed the hair-cell MET channel as a viable target for the identification of compounds that 
protect the cochlea from aminoglycosides and provide a series of hit compounds that will inform 
the design of future otoprotectants.
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mature mouse utricles from neomycin in vitro (22). Subsequent phenotypic optimization of  PROTO-1 
led to the development of  ORC-13661, an orally available derivative that preserves hearing in rats 
treated with the aminoglycoside amikacin (23) and prevents hair-cell death in mouse cochlear cultures 
exposed to either the ototoxic anticancer reagent cisplatin or the aminoglycoside gentamicin (24). Fur-
thermore, ORC-13661 is a high-affinity permeant blocker of  the mechano-electrical transducer (MET) 
channel, an established route of  aminoglycoside entry into hair cells (25–28).
The clinical effectiveness of  ORC-13661 remains to be determined, and it would be advantageous 
if  a broader repertoire of  potential protectants was available. Neomycin, used in the zebrafish Diverse 
E library screen (22), and gentamicin, widely used in neonatal intensive care units (29), differ in the 
way in which they kill hair cells (30). Furthermore, the concentration of  neomycin (200 μM) used in 
the zebrafish Diverse E screen (22) is in considerable excess of  the endolymphatic gentamicin con-
centration (~2 μM) measured in rats with plasma levels comparable to those of  patients treated with 
this drug (31). Although high aminoglycoside concentrations provide a time-saving advantage in mod-
erate-to-high throughput screens, one may miss compounds effective against lower, but nonetheless 
clinically relevant, concentrations of  aminoglycosides.
In light of  these concerns, a Life Chemicals Diversity Set of  compounds covering a broad range of  
chemical space was screened using zebrafish larvae in a pipeline that used 2 aminoglycosides at lower 
concentrations and involved 3 sequential selections: the first with zebrafish and neomycin, the second 
with zebrafish and gentamicin, and the third with mouse cochlear cultures and gentamicin. The zebraf-
ish screens provided a high yield of  compounds (64 in total) that protected against both neomycin and 
gentamicin, 8 of  which provided protection against gentamicin in mouse cochlear cultures. These hits 
all interact with the MET channel to varying degrees, and suggest this hair-cell entry route for amino-
glycosides is a viable target for the future development of  otoprotectants.
Results
Screening for protectants with zebrafish larvae and mouse cochlear cultures. Initially, 10,240 compounds from 
the Life Chemicals Diversity Set (Figure 1A) were screened at a concentration of  25 μM for ability 
to protect hair cells in the lateral-line organs of  zebrafish larvae from exposure to 6.25 μM neomycin. 
This approach (see Supplemental Methods; supplemental material available online with this article; 
https://doi.org/10.1172/jci.insight.145704DS1) yielded 477 compounds (Figure 1B), which were 
retested at 50 μM for their ability to protect the zebrafish hair cells from death caused by exposure to 
10 μM gentamicin (Figure 1C). From these 2 screens, 64 compounds were identified (Figure 1C) that 
protected zebrafish lateral-line hair cells against both neomycin and gentamicin. These 64 compounds 
were then tested at 50 μM for their ability to protect outer hair cells (OHCs) in mouse cochlear cultures 
from exposure to 5 μM gentamicin. Based on qualitative assessments, 20 compounds were identified 
that protected mouse cochlear OHCs against gentamicin-induced cell death (Figure 1D), 8 of  which 
protected hair cells without causing overt signs of  hair-bundle damage (Figure 1E). Examples of  neu-
romasts and cochlear cultures treated with aminoglycoside alone or aminoglycoside in the presence of  
a typical hit compound at each stage of  this screen are shown in Figure 1, F–M. The chemical identi-
fiers of  all compounds tested and those selected at each step in the screen can be viewed in the inter-
active polar scatterplots (see https://sussex-neuroscience.github.io/Identification-of-a-series-of-hair-
cell-MET-channel-blockers/Supplemental%20Data%20Polar%20Scatterplot.html and instructions in 
Supplemental Figure 1). Given that changes in hair-bundle structure are associated with resistance to 
aminoglycoside toxicity (32), the 8 compounds (Figure 1E) that protected OHCs without causing overt 
signs of  hair-bundle damage (Figure 1, L and M) were selected and characterized further.
Characterization of  identified otoprotectants. Further characterization of  the protectants identified 
above included (a) quantitating OHC numbers in cochlear cultures treated with gentamicin together 
with the compound, (b) ascertaining whether the compound is cytotoxic in vitro at higher concen-
trations, and (c) determining whether the compound blocks either the basolateral potassium current 
(IK,neo) or the MET channel of  early postnatal OHCs.
Analysis of  the numbers of  OHCs surviving 48 hours of  exposure to 5 μM gentamicin in the pres-
ence of  50 μM of  each of  the 8 hit compounds (Figure 2) revealed that all were protective, with the 
numbers of  OHCs being significantly higher than those in cultures exposed to 5 μM gentamicin alone. 
The protection provided by UoS-9645 was, however, inconsistent (Figure 2H), and OHC numbers 
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were significantly lower (P < 0.001) than those in control cultures not exposed to gentamicin. When 
these 8 compounds were tested at a concentration of  100 μM in the absence of  gentamicin for 48 hours 
(Figure 3), UoS-5247 (Figure 3D) caused a complete loss of  basal-coil hair cells, and UoS-8052 (Figure 
3G) caused a substantial loss of  OHCs.
OHCs in early postnatal mice express a voltage-dependent basolateral potassium current, IK,neo (33), 
and depolarization with high extracellular K+ protects OHCs in cochlear cultures from aminoglycosides 
(21). A block of  IK,neo over the duration of  the protection assay (48 hours) could cause a degree of  depo-
larization, reducing the driving force for aminoglycoside entry into hair cells via the MET channel and 
thereby causing protection. To determine whether any of  the 8 compounds interact with IK,neo, basolat-
eral potassium currents were recorded in response to voltage-steps from –154 to +46 mV before, during, 
and after superfusion with 50 μM of  each compound (Figure 4). Examples of  recordings obtained with 
2 of  the compounds are shown in Figure 4, A and B. UoS-5247 reversibly reduced the size of  IK,neo 
during superfusion, with the currents recovering after washout with control solution (Figure 4, A and 
C), whereas UoS-7692 was without effect (Figure 4, B and D). Average current-voltage curves, normal-
ized to the control current at +46 mV for each cell, showed that 6 of  the compounds blocked IK,neo to a 
variable extent (Figure 4E) and that 2 did not (Figure 4F).
The MET channel is a route of  aminoglycoside entry into sensory hair cells (25–28), and various 
MET channel blockers provide protection against aminoglycoside toxicity (20, 24, 34–36). To assess 
channel block as a protective mechanism, interactions between the MET channel and the 8 compounds 
identified from the initial screen were investigated. MET currents elicited by hair-bundle stimulation 
were recorded from OHCs at membrane potentials ranging from –164 mV to +96 mV before, during, 
Figure 1. Screen of 10,240 Life Chemicals Diversity compounds in zebrafish larvae and mouse cochlear cultures. (A) Dendrogram of compounds grouped by 
broadly related structure into 5 clusters identified by color. (B–E) Polar scatterplots annotated with dendrogram clusters. Blue dots show “hit” compounds in each 
cluster obtained in each screen (see Supplemental Figure 1). Blue arrows between the plots indicate compounds passing the previous screen were used in the 
next. (F–M) Representative examples of neuromasts (F–I) and cochlear cultures (J–M) treated with antibiotic alone (F, H, J, and L) or antibiotic in the presence of 
one of the hit compounds (G, I, K, and M). Neuromasts (F–I) were labeled with YO-PRO-1 prior to incubation with neomycin alone (F), neomycin and UoS-3606 (G), 
gentamicin alone (H), or gentamicin and UoS-3606 (I). Cochlear cultures (J–M) were labeled with Texas red phalloidin after treatment with gentamicin alone (J and 
L) and gentamicin with UoS-7339 (K) or UoS-3606 (M). Hair bundles in K show damage; those in M are normal. Scale bars: 20 μm (J–M). 
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and after extracellular perfusion with 50 μM of  each compound (Figure 5). Examples of  these currents 
are shown for compound UoS-7691, a weak blocker (Figure 5A), and UoS-8052, a stronger blocker 
(Figure 5C). The block was partially reversible when superfusion with control solution was resumed 
for UoS-8052 but not for UoS-7691 (Figure 5, B and D). Fractional block curves were generated, and 
the current was measured during exposure to the compounds relative to the control current recorded 
before perfusion plotted at each membrane potential (Figure 5E). All 8 compounds interacted with the 
MET channel, reducing currents across the entire range of  membrane potentials to a greater or lesser 
degree. UoS-3606 and UoS-7692 provided the strongest block, whereas UoS-9645 and UoS-7691 were 
the weakest MET channel blockers.
Figure 2. Compounds protecting mammalian cochlear hair cells from gentamicin without visible damage to the hair 
bundles. (A–H) Graphs showing the numbers of surviving OHCs in a region of interest (ROIs) 20% from the basal end of 
the cochlea in cultures exposed to low-serum medium (LSM), LSM with 5 μM gentamicin, or LSM with 5 μM gentamicin 
and 50 μM of (A) UoS-962, (B) UoS-3606, (C) UoS-3607, (D) UoS-5247, (E) UoS-7691, (F) UoS-7692, (G) UoS-8052, and (H) 
UoS-9645. DMSO at 0.5% in all conditions. Each compound was tested on the following number of independent occasions 
alongside a control and 5 μM gentamicin condition: UoS-962 (n = 4), UoS-3606 (n = 4), UoS-3607 (n = 4), UoS-5247 (n = 4), 
UoS-7691 (n = 4), UoS-7692 (n = 6), UoS-8052 (n = 3), and UoS-9645 (n = 6); additionally, in some instances compounds 
were tested twice within 1 experiment. One-way ANOVA with Tukey’s multiple-comparison test revealed all compounds 
were protective, with numbers of OHCs in the presence of test compounds and gentamicin significantly different from 
cultures exposed to gentamicin alone. Numbers of OHCs in cultures incubated with gentamicin and UoS-9645 were 
significantly lower than those in cultures exposed to LSM alone. Symbols represent individual replicates. Each symbol 
represents numbers of OHCs in a mid-basal ROI from 1 culture. Error bars show standard deviation of the mean (SDM).  
*P < 0.05; **P < 0.01; ***P < 0.001; NS, no significant difference. Representative images of the ROI from cultures exposed 
to LSM with 5 μM gentamicin and 50 μM of each compound show the protection offered, with phalloidin-stained hair 
bundles clearly visible. Scale bar: 25 μm.
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UoS-7692 thus provided complete protection of  OHCs at 50 μM when tested against 5 μM gentami-
cin and was not toxic when tested alone at 100 μM. UoS-7692 also blocked the MET channel, but it did 
not block IK,neo and is therefore unlikely to reduce drug entry indirectly. On the basis of  these properties, 
it was selected for further detailed characterization to determine (a) dose-response relationships, (b) the 
ability to protect against different aminoglycoside antibiotics, (c) the impact on the bactericidal activity of  
gentamicin, (d) a likely mechanism of  action, and (e) if  it would provide protection of  the cochlea in vivo.
Dose-response relationship for protection of  mouse OHCs by UoS-7692. To determine the EC50 for UoS-
7692, the concentration at which it provides half-maximal protection from gentamicin damage, cochlear 
cultures were exposed to 5 μM gentamicin for 48 hours with concentrations of  UoS-7692 varying from 
3 to 100 μM. Numbers of  surviving OHCs in the mid-basal region were counted and a dose-response 
function was generated (Figure 6A). This function was fit with the equation: 
 
 (Equation 1)  
where nOHC is OHC count, [C] concentration of  protective compound, and nH the Hill coefficient. 
The baseline is the average number of  OHCs remaining in the mid-basal region of  interest (ROI) in 
cultures exposed to 5 μM gentamicin (4 ± 3 OHCs, n = 7), and maximum survival is the average num-
ber of  OHCs in the same region in control cultures (79 ± 8 OHCs; n = 6). The EC50 value for UoS-7692 
was 8.1 μM, and the Hill coefficient was 2.5.
UoS-7692 also protects mouse OHCs against kanamycin and tobramycin. To determine whether UoS-7692 
would provide protection against other clinically relevant aminoglycosides, it was tested against tobra-
mycin and kanamycin in mouse cochlear cultures. As shown in Figure 6B, at 50 µM UoS-7692 was found 
to protect against hair-cell loss induced by either 20 µM tobramycin or 75 µM kanamycin, concentrations 
of  the 2 aminoglycosides that caused a substantial loss of  OHCs in the mid-basal coil in the absence of  a 
protectant.   UoS-7692 was therefore able to protect hair cells against multiple aminoglycosides.
UoS-7692 does not compromise the antibacterial activity of  gentamicin. When tested against 3 clinically relevant 
bacterial pathogens, Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa, the bactericidal 
properties of gentamicin were unaffected in the presence of a 5× higher concentration of UoS-7692 (Figure 7).
UoS-7692–MET channel interaction reveals potential protective mechanism. To characterize the interac-
tion between UoS-7692 and the MET channel, MET currents were recorded at different membrane 
Figure 3. UoS-5247 and UoS-8052 are cytotoxic at a concentration of 100 μM. (A–H) Representative images from the mid-basal ROI of Texas red phalloi-
din-stained cultures that were exposed to 100 μM of UoS-962 (A), UoS-3606 (B), UoS-3607 (C), UoS-5247 (D), UoS-7691 (E), UoS-7692 (F), UoS-8052 (G), 
and UoS-9645 (H) alone for 48 hours. UoS-5247 (D) and UoS-8052 (G) show widespread cell death. Images are representative of n = 2 experiments. UoS-
8052 was selectively toxic to OHCs, whereas UoS-5247 killed both inner and outer hair cells. Scale bar: 25 μm.
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potentials before, during, and after extracellular perfusion with 50 μM UoS-7692 (Figure 8A). The 
corresponding current-voltage curves (Figure 8B) showed some recovery of  the current after washout 
with control solution, indicating that the block was reversible. The recovery was not as immediate as 
that previously reported for other MET channel blockers, including d-tubocurarine and berbamine 
(34), and took time to develop, suggesting UoS-7692 does not readily dissociate from the channel.
To determine how the block varied with concentration, currents were recorded during extracellular 
exposure to concentrations of  UoS-7692 between 1 and 50 μM. Dose-response curves derived from the 
currents measured at each membrane potential (selected membrane potential levels shown in Figure 
8C) revealed an increase in the block with increasing concentrations of  UoS-7692. The half-blocking 
concentrations (KD) and Hill coefficients determined from each dose-response curve are shown in Fig-
ure 8D. The KD values at extreme hyperpolarized and depolarized potentials were 21.5 μM and 28.2 
μM, respectively, dropping to 12.0 μM at –24 mV, reflecting a stronger block at intermediate potentials 
(Figure 8D). The Hill coefficients ranged from 1.1 to 2.1 (Figure 8D), suggesting that more than one 
molecule of  UoS-7692 binds to the channel, showing positive cooperativity (37). At the resting poten-
tial of  early postnatal mouse OHCs (–55 to –60 mV; refs. 21, 33, 38), the KD was 12.4 μM (Figure 8C), a 
value close to that found for the EC50 of  UoS-7692 in the hair-cell protection assay (8.1 μM, Figure 6A).
Average fractional block data confirmed the increase in the level of  the block with increasing con-
centration of  UoS-7692 (Figure 8E). At the higher concentrations (10–50 μM), there was a release of  
the block at both the extreme depolarized and hyperpolarized potentials, with release at hyperpolar-
ized potentials indicative of  a permeant blocker. The fractional block data were fitted with Equation 
4, described in the Methods. From the fits, it can be deduced that UoS-7692 blocks maximally at a 
membrane potential of  –3 mV, is positively charged (valence +0.73), and that it binds (binding energy 
Figure 4. Compounds UoS-7692 and UoS-9645 do not block IK,neo. (A and B) Basolateral currents measured from mid-basal coil OHCs in response to a series of 
voltage steps from a holding potential of –84 mV before, during, and after extracellular exposure to 50 μM UoS-5247 (A) and 50 μM UoS-7692 (B). Schematic 
representation of the voltage-step protocol is shown below each of the current traces. Cell capacitances were 6.8 pF (A) and 7.0 pF (B). (C and D) Current-voltage 
curves measured from cells exposed to 50 μM UoS-5247 (C) and UoS-7692 (D) before, during, and after compound superfusion. (E and F) Average steady-state 
current-voltage curves of the 8 protective compounds at 50 μM. Currents normalized to steady-state control current at +46 mV for each cell. Cell numbers: UoS-
962 (n = 2); UoS-3606 (n = 2); UoS-3607 (n = 2); UoS-5247 (n = 5); UoS-7691 (n = 4); UoS-7692 (n = 4); UoS-8052 (n = 5); UoS-9645 (n = 5).
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–17.0 kT) to a site with a relative electrical distance, as a fraction of  the transmembrane electrical field, 
of  0.69 from the outside of  the membrane. The binding site for UoS-7692 is close to that for dihydrost-
reptomycin (relative electrical distance from the outside = 0.79), but it binds much more strongly (the 
binding energy for dihydrostreptomycin under similar conditions was –8.27 kT).
UoS-7692 blocks uptake of  gentamicin conjugated to Texas red. Although the decrease in MET current 
size in the presence of  UoS-7692 showed that this compound blocked the MET channel, it is important 
to determine whether UoS-7692 decreases aminoglycoside loading. To assess this, cultures were incu-
bated with 100 μM UoS-7692 for 5 minutes and gentamicin conjugated to Texas red (GTTR) was added 
for a further 10 minutes before washout and imaging. Incubation with GTTR in the presence of  DMSO 
resulted in strong labeling of  the OHCs (Figure 9A). After incubation with GTTR in the presence of  
UoS-7692 (Figure 9B), the average level of  GTTR loading was reduced significantly (Figure 9C).
UoS-7692 preserves larval movement in neomycin-treated zebrafish. Zebrafish are a powerful in vivo 
model for assessing the protective potential of  compounds, and although many studies have sought to 
Figure 5. All 8 hit compounds block the MET channel to varying degrees. (A) MET currents recorded from an OHC before, during, and after extracellular 
exposure to 50 μM UoS-7691. Currents were recorded at membrane potentials ranging from –164 to +96 mV with channel opening and closing achieved 
by a sinusoidal stimulus delivered to the fluid jet (driver voltage, DV). (B) Current-voltage curves before, during, and after extracellular exposure to 50 μM 
UoS-7692 derived from currents shown in A. Cell capacitance was 8.2 pF. (C) MET currents from another OHC before, during, and after exposure to 50 μM 
UoS-8052. (D) Current-voltage curves derived from the currents shown in C. Cell capacitance was 7.0 pF. (E) Average fractional block curves (mean ± SEM) 
for all 8 compounds at 50 μM. Cell numbers: UoS-962 (n = 7); UoS-3606 (n = 4); UoS-3607 (n = 4); UoS-5247 (n = 4); UoS-7691 (n = 3); UoS-7692 (n = 3); UoS-
8052 (n = 4); UoS-9645 (n = 9).
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identify compounds that prevent lateral-line hair-cell loss after aminoglycoside exposure, none have 
determined whether the continued presence of  hair cells correlates with preserved behavioral respons-
es. When treated with 6.25 μM neomycin for 1 hour, 5 dpf  larvae showed reduced movement after 
washout compared with control larvae (Figure 10A). After cotreating larvae with 6.25 μM neomycin 
in the presence of  25 μM UoS-7692, larval movement after washout was not significantly different 
from that in untreated controls but was significantly greater than movement in larvae treated with 
Figure 6. Dose-response function for gentamicin protection with UoS-7692 and protection from tobramycin and 
kanamycin by UoS-7692. (A) Dose-response graph showing average number of OHCs in mid-basal ROI from cultures 
exposed to LSM with 5 μM gentamicin and 3–100 μM UoS-7692 for 48 hours. Graph fitted with equation 1. EC50 value 
of UoS-7692 is 8.1 μM. Number of cultures: 3 μM (n = 3); 10 μM (n = 5); 30 μM (n = 3); 50 μM (n = 6); 100 μM (n = 3). Error 
bars show SEM. (B) Micrographs of mid-basal region of cochlear cultures incubated for 48 hours in 20 μM tobramycin 
(left) or 75 μM kanamycin (right) without (top) or with (bottom) 50 μM UoS-7692. Scale bar: 25 μm. Quantification of 
OHC survival showed protection from tobramycin- and kanamycin-induced hair-cell death. One-way ANOVA with Tukey’s 
multiple-comparison test. **P < 0.01; ***P < 0.001. Experiments were performed on 3 independent occasions. Symbols 
represent data from individual cells. Error bars show SDM.
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neomycin alone (Figure 10A). Labeling with YO-PRO-1 confirmed that hair cells were absent in lar-
vae treated with neomycin alone but still present in hair cells cotreated with neomycin and UoS-7692 
(Figure 10B). Treatment of  larvae with 25 μM of  UoS-7692 alone did not significantly reduce larval 
movement after washout relative to control larvae (Figure 10C).
UoS-7692 protects mouse cochlear hair cells from furosemide/kanamycin exposure in vivo. Super-resolution 
microscopy and quantification of  the numbers of  OHCs were used to determine whether transtympanic 
delivery of  UoS-7692 provides protection in vivo from i.p. injection of  a loop diuretic (furosemide) fol-
lowed by aminoglycoside (kanamycin), a procedure reported to cause rapid, reliable, and extensive loss of  
hair cells (39). Confocal images collected at defined points along the cochlea from mice 2 days after furo-
semide/kanamycin exposure revealed that UoS-7692–injected ears typically retained a full complement of  
OHCs in regions 40% and 60% from the apical, low-frequency end (Figure 11, A and C), whereas substan-
tial OHC loss was seen in ears that did not receive UoS-7692 (Figure 11, B and D). In the 80% region, the 
OHC complement was near normal in the UoS-7692–injected ears (Figure 11E), whereas OHC loss was 
extensive in ears that did not receive UoS-7692 (Figure 11F). Nine days after furosemide/kanamycin expo-
sure, OHC numbers in the 20% (not shown) and 40% regions (Figure 11G) were normal in ears that had 
received UoS-7692. Some loss, however, was observed in the 60% region (Figure 11I), and a total loss of  
OHCs was seen in the more basal, 80% region (Figure 11K). In noninjected ears of  mice exposed to furose-
mide/kanamycin alone, there was total loss of  OHCs in all regions (20% [data not shown], 40%, 60%, and 
80% from apical end) after 9 days (Figure 11, H, J, and L). In surviving hair cells, hair bundles were typi-
cally intact and of  normal appearance. Staining with prestin antibodies revealed the cell bodies of  surviving 
OHCs also appeared normal (Supplemental Figure 2). Hair-cell complement and hair-bundle morphology 
were normal in ears that received either UoS-7692 or 5% DMSO without subsequent systemic furosemide/
kanamycin treatment and in cochleae from animals that received furosemide alone (data not shown).
Figure 7. Antimicrobial activity of gentamicin is unaffected by the presence of UoS-7692. Box-and-whisker plots of ATP 
luminescence as a measure of bacterial viability in Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeru-
ginosa grown in 2.2 μM gentamicin in the presence or absence of 11 μM UoS-7692. There was no change in the bactericidal 
activity of gentamicin in the presence of UoS-7692. UoS-7692 was tested with 3 technical replicates and 3 independent 
biological replicates. Midline = median, boxes = IQR, whiskers = an additional 1.5 × IQR; replicates are shown as open 
circles with biological replicates grouped by color. Staphylococcus aureus (t = 1.55, df = 14, P = 0.143), Klebsiella pneumoniae 
(t = 1.44, df = 13, P = 0.175), and Pseudomonas aeruginosa (t = 1.71, df = 14, P = 0.11) using a linear mixed-effects model.
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Quantification of  OHC numbers (Figure 11M) indicated that there was significant loss of  OHCs 
in all regions 2 days after furosemide/kanamycin exposure and that this was not alleviated by tran-
stympanic injection (TTI) of  5% DMSO alone (Figure 11M, group 1). However, TTI of  UoS-7692 
(in 5% DMSO) resulted in significant increases in OHC numbers surviving furosemide/kanamycin 
exposure relative to those in noninjected ears in all regions (Figure 11M, group 2).
UoS-7692 partially preserves hearing in mice after furosemide/kanamycin exposure. Auditory brainstem 
response (ABR) thresholds for click and pure-tone stimuli were also measured to determine the extent 
to which transtympanic delivery of  UoS-7692 would protect hearing in mice treated with furose-
mide/kanamycin. ABRs recorded from mice 9 days after TTI of  5% DMSO in both ears without sub-
sequent furosemide/kanamycin exposure revealed a small, nonsignificant elevation in ABR thresh-
olds (Figure 12A, black line/symbol), relative to those of  control mice. Mice that received UoS-7692 
in both ears, but were not exposed to furosemide/kanamycin, had threshold shifts greater than 50 dB 
after 2 days (Figure 12A, dashed light-green line/diamonds). However, 9 days after TTI of  UoS-7692 
alone, these threshold shifts were much reduced (Figure 12A, dark-green line/diamonds) and not 
significantly different from those following TTI of  DMSO alone. UoS-7692 alone therefore caused 
a temporary threshold shift, as would be expected for a MET channel blocker and probably due to a 
slow clearance rate from the inner ear.
Two days after exposure to furosemide/kanamycin alone, and as expected from the observed loss 
of  OHCs (see Figure 11, B, D, F, and M), auditory thresholds were significantly increased relative to 
those in controls that were transtympanically injected with DMSO but not treated with furosemide/
kanamycin, both for clicks and at all pure-tone frequencies tested (Figure 12B, red symbols). With 
prior TTI of  UoS-7692, auditory thresholds were also increased 2 days after furosemide/kanamycin 
exposure (Figure 12, light-blue line/squares), even though OHC numbers were normal (see Figure 11, 
A, C, E, and M). After 9 days, however, although minimal improvement was seen at 24 and 30 kHz, 
Figure 8. UoS-7692 is a strong MET channel blocker at 50 μM. (A) MET currents recorded from an OHC before, during, and after extracellular exposure to 50 
μM UoS-7692. Currents elicited by sinusoidal fluid-jet stimulation (DV) and recorded at membrane potentials ranging from –164 to +96 mV. (B) Current-voltage  
curves before, during, and after extracellular exposure to 50 μM UoS-7692. Cell capacitance was 7.4 pF. (C) Average dose-response curves for MET channel 
block by UoS-7692, fitted to equation 2. For clarity, data for only 4 selected membrane potentials are shown. (D) KD and Hill coefficient from dose-response 
curves fitted to data recorded at each membrane potential. (E) Average fractional block curves showing current during UoS-7692 superfusion relative to control 
current at each membrane potential. Curves are fits to a 2-barrier 1 binding-site model (equation 3). Fit parameters: ΔE 0.0 kT (95% CI –1.2 to 1.2 kT); Eb –17.0 
kT (95% CI –18.3 kT to –15.7 kT); δb 0.69 (95% CI 0.51 to 0.87); z 0.73 (95% CI +0.72 to +0.74); nH 1.45 (95% CI 1.34 to 1.56). Number of OHCs in B–D: 1 μM (n = 4); 
3 μM (n = 4); 10 μM (n = 4); 30 μM (n = 3); 50 μM (n = 3); error bars show SEM.
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mice that received transtympanic UoS-7692 followed by furosemide/kanamycin (Figure 12B, dark-blue 
line/squares) had significantly improved thresholds at 12 and 18 kHz, relative to those measured 2 days 
after furosemide/kanamycin alone (Figure 12B, red line/triangles). Improvements of  approximately 30 
dB were observed for clicks and 12 kHz tones. Therefore, although transtympanic application of  UoS-
7692 caused a temporary loss of  hearing, it largely prevented hair-cell loss throughout the cochlea and 
reduced, at lower frequencies, deafness caused by loop diuretic/aminoglycoside treatment.
Discussion
The results describe a screen of  10,240 compounds identifying 8 hits that provide protection against 
gentamicin-induced hair-cell loss in mouse cochlear cultures without causing overt hair-bundle damage. 
After further selection using stringent criteria, UoS-7692 was characterized in depth. UoS-7692 sig-
nificantly reduced GTTR accumulation in mouse OHCs in vitro, did not compromise the bactericidal 
properties of  gentamicin, and protected zebrafish against the behavioral consequences of  neomycin- 
induced hair-cell loss. Furthermore, UoS-7692 protected hair cells and partially preserved hearing in 
mice after exposure to a combination of  an aminoglycoside and a loop diuretic, a procedure that elimi-
nates almost all cochlear OHCs within 48 hours (39).
Despite the chemical diversity of  the library, all of  the initial hits were found to interact to varying 
degrees with the MET channel, an established entry route for aminoglycosides into hair cells (25–28). 
To our knowledge, none of  these 8 hits have been reported yet to have any biological effect against 
other targets nor are similar to ORC-13661. The structure of  these 8 hits is shown in Figure 13 with 
various moieties outlined in different colors. With the exception of  UoS-9645 and UoS-5247, these 
compounds share 3 main parts, which include 2 aromatic moieties linked together by a cyclic amine; 
the latter is either piperidine (blue for UoS-7692, UoS-7691, UoS-8052, UoS-3607, UoS-3606, and 
UoS-9645) or piperazine (green for UoS-5247 and UoS-962). As previously reported (21, 34, 36), the 
presence of  a basic amine or quaternary nitrogen (i.e., protonated at plasma pH) is required for the 
interaction with the MET channel. One of  the aromatic moieties, benzimidazole, is recurrent for 5 
compounds (red for UoS-7692, UoS-7691, UoS-8052, UoS-3607, and UoS-3606) but is linked differ-
ently with regard to position in the benzimidazole ring and to the spacer between the benzimidazole 
and the piperidine ring. Compounds UoS-5247 and UoS-962 have, instead, a monocyclic aromat-
ic ring (orange), meta-chlorophenyl and pyridine, respectively. The second aromatic moiety, despite 
being variable, is generally lipophilic (magenta); the exception is UoS-7691, which bears a furan ring 
(purple). A lipophilic moiety is also shared by UoS-5247, which, despite lack of  a second aromatic 
Figure 9. UoS-7692 reduces GTTR loading in cochlear hair cells. Representative micrographs of GTTR fluorescence 
in cochlear cultures incubated with DMSO (A) and UoS-7692 (B) prior to the addition of GTTR. Scale bar: 25 μm. (C) 
Comparison of GTTR fluorescence levels in AU by 2-tailed unpaired t test shows a reduction in GTTR loading in cultures 
treated with UoS-7692 (***P < 0.001). Symbols represent individual OHC fluorescence levels (10 cells from 3 control and 
4 UoS-7692–treated cultures: different colors indicate the 3 independent experimental repeats). Error bars show SDM. 
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system, has a lipophilic side chain (maroon). UoS-9645 has the piperidine ring (blue) and a lipophilic 
chlorophenyl ring (magenta), but it lacks the second aromatic moiety.
The effects of  the 8 initial hits on OHC MET currents showed that the compounds bearing a 
benzimidazole moiety interacted more strongly with the MET channel, with compounds UoS-7692, 
UoS-8052, UoS-3607, and UoS-3606 providing a more than 70% block of  MET current at 50 μM. The 
exception was UoS-7691, which only provided a 20% block. UoS-7691 has the least lipophilic moiety 
(a furan ring, purple), compared with the more lipophilic rings of  other compounds (magenta), and 
this may account for its reduced efficacy. The apparent requirement of  a lipophilic aromatic moiety 
for enhanced block is of  interest given recent findings indicating the ion conduction pathway of  the 
MET channel subunit, TMC1, may be a groove that abuts the lipid bilayer (40, 41). Lipophilicity may 
therefore facilitate interactions of  the compounds with negatively charged aminoglycoside binding 
sites lying deep in the conduction path.
Previous studies (21, 34, 36) have established the necessity of  either a fixed positive charge or a pH- 
dependent positively charged moiety, usually a nitrogen with a pKa 37.5. The most effective channel 
blockers were UoS-3606 and UoS-7692, both of  which, at 50 μM, provided a block of  the MET current 
of  approximately 80%. UoS-3606 had the highest calculated pKa (8.8), and more than 90% of  mole-
cules are expected to be positively charged at plasma pH (7.4). With a calculated pKa of  6.2, UoS-7692 
is predicted to be only partially protonated at physiological pH, and it is less easy to interpret how it 
interacts with the MET channel. The combination of  substituents (benzimidazole and difluorophenyl) 
may, however, favor a stronger interaction with the MET channel and thus contribute to the strong 
block observed with UoS-7692. Similarly, the 70% block provided by UoS-8052 and UoS-3607, each 
of  which are partially protonated (~50% at pH 7.4), suggests benzimidazole and a lipophilic aromat-
ic moiety are both needed for a strong interaction with and block of  the MET channel. Finally, the 
steep release of  the MET current block seen with UoS-962 and UoS-5247 at hyper- and depolarized 
potentials, along with the very weak block of  the MET current observed with UoS-9645, indicate the 
benzimidazole moiety favors interactions with the MET channel.
Figure 10. UoS-7692 preserves larval movement in neomycin-treated zebrafish. (A) Box-and-whisker plots showing movement of 5 dpf zebrafish larvae after 
treatment with E3 medium, 6.25 μM neomycin, or 25 μM UoS-7692 and 6.25 μM neomycin, followed by washout. Circles show individual larvae with indepen-
dent experiments grouped by color (n = 3). (B) Images of example neuromasts labeled with YO-PRO-1 after treatment with E3 medium (top), 6.25 μM neomy-
cin (middle), or 25 M UoS-7692 and 6.25 μM neomycin (bottom) after behavioral testing. Scale bar: 20 μm. (C) Box-and-whisker plots showing movement of 5 
dpf zebrafish after treatment with either E3 medium or 25 μM UoS-7692 alone followed by washout. Circles show individual larvae with independent exper-
iments grouped by color (n = 4). Black line shows median, gray boxes span the IQR, and whiskers extend over points within additional 1.5 × IQR. Neomycin 
compared with control larvae P = 0.029, neomycin and UoS-7692 compared with control larvae P = 0.3947, neomycin and UoS-7692 compared with neomycin 
alone larvae P = 0.0153 (Dunn’s post hoc tests). UoS-7692 alone compared with control larvae t = 0.552, df = 126, P = 0.58 using a 2-sample t test. *P < 0.05.
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The model used (27, 42) to fit the MET channel fractional block data provides further insight into the 
mechanism whereby UoS-7692 is likely to be providing protection. Despite predictions from the pKa, the 
fits suggest UoS-7692 has a modest positive charge of  +0.73. Furthermore, the binding site for UoS-7692 
is predicted to be deep inside the channel at a relative electrical distance of  0.69, a position very similar 
to that of  the aminoglycoside binding site. The model also predicts UoS-7692 binds very tightly to the 
MET channel, more strongly than the aminoglycosides, with a high binding energy comparable to the 
otoprotectant carvedilol and its derivative compound 13 (36). Overall, these findings suggest UoS-7692 is 
competing directly with aminoglycosides at a binding site located in the ion conduction pathway of  the 
MET channel, a suggestion supported by its ability to block GTTR loading. However, UoS-7692 and the 
other hit compounds all behave as permeant blockers of  the MET channel and may therefore operate as 
protectants, alternatively or additionally, at intracellular sites downstream of  hair-cell entry.
Figure 11. Transtympanic injection of UoS-7692 protects OHCs from systemic kanamycin treatment. (A–L) Assessment of OHC-bundle morphology with 
phalloidin staining in regions 40% (A, B, G, and H), 60% (C–D, I, and J), and 80% (E, F, K, and L) from the cochlear apex in mice receiving transtympanic 
injection of UoS-7692 in 1 ear (A, C, E, G, I, and K) and no injection in the opposite ear (B, D, F, H, J, and L), followed by systemic furosemide/kanamycin. Mice 
were maintained for either 2 (A–F) or 9 (G–L) days. In UoS-7692–treated ears after 2 days, there was minimal or no OHC loss in all regions; in untreated ears, 
OHC loss was extensive, particularly in the 60% and 80% regions. In UoS-7692–treated ears after 9 days, some OHC loss was observed in the 60% region (I) 
and total loss seen in the 80% region (K); in untreated ears, there was total loss of OHCs in all regions (H, J, and L). Scale bar: 20 μm. (M) Graphs comparing 
OHC numbers in cochleae of noninjected (red symbols) and injected (brown and blue symbols) ears of mice 2 days after unilateral transtympanic application 
of 5% DMSO (brown symbols) or 50 mM UoS-7692 in 5% DMSO (blue symbols), followed by systemic furosemide/kanamycin (groups 1 and 2) or no treat-
ment (group 3). Numbers of mice: group 1 (n = 5), group 2 (n = 9), group 3 (n = 2). OHCs were counted in 140 μm length regions located 40%, 60%, and 80% 
from the cochlear apex. UoS-7692 provided significant protection in all 3 regions (2-way ANOVA with matched pairs design between cochleae from the same 
animal, with Šidák’s multiple-comparison test between injected and noninjected ears. ***P < 0.001). Scale bar: 20 μm. Error bars show SDM.
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The protectants discovered in this study add considerably to those that have been identified pre-
viously and are also known to interact with the MET channel, such as amiloride, benzamil, berbam-
ine, carvedilol, d-tubocurarine, hexamethyleneamiloride, ORC-13661, and quinine (20, 25, 34, 36, 
43–47). Although the MET channel may therefore be a good target for informing the design of  an 
otoprotectant that could be coadministered with aminoglycosides to prevent hair-cell death, this study 
raises the question of  whether compounds that are likely to block the MET channel transiently are a 
realistic and clinically acceptable option for providing protection against aminoglycosides. Despite 
this concern, a recent study with ORC-13661 in rats indicates that a systemically applied MET chan-
nel blocker can provide protection against aminoglycosides without causing auditory threshold shifts 
during treatment (24). A likely explanation, based on the observation that patients only experience 
deafness after, and not during, treatment with aminoglycosides, is that cochlear hair cells accumulate 
aminoglycosides at a low rate from scala media, an extracellular compartment in which the amino-
glycoside concentration may never be very high (31, 48). If  so, relatively low concentrations of  MET 
channel–blocking otoprotectants may suffice to compete for entry and reduce aminoglycoside accumu-
lation in hair cells to levels below those required to instigate cell death. Once optimized for systemic 
delivery, and if  tested in a longer-term model with repeated systemic application of  aminoglycoside, 
a compound based on UoS-7692 may also protect hair cells in vivo at a much lower dose and without 
causing a temporary shift in auditory thresholds.
In conclusion, this study led to the identification of  8 protective compounds, all of  which are block-
ers of  the MET channel. As such, it provides further confirmation that this channel is a viable target for 
the design of  otoprotectants. The structures and properties of  these compounds, some of  which are quite 
closely related, together with those of  MET channel–blocking protectants already known, provide a 
Figure 12. Transtympanic injection of UoS-7692 reduces kanamycin-induced hearing loss in mice. (A) ABR thresholds shifts from baseline (0 dB) 
measured 9 days after bilateral trans-tympanic injection (BTTI) of 5% DMSO (black circles, black line), 2 days after BTTI of 50 mM UoS-7692 (light-green 
diamonds, dashed line), and 9 days after BTTI of 50 mM UoS-7692 (dark-green diamonds, solid line). UoS-7692 induced significant temporary threshold 
shifts at 2 days, which were resolved by 9 days (1-way ANOVAs for click and individual pure-tone frequencies with Dunnett’s multiple-comparison test 
between UoS-7692 at 2 and 9 days and DMSO at 9 days). Significance levels for differences between UoS-7692 at 2 days and DMSO at 9 days are indicated 
by light-green asterisks. (B) ABR threshold shifts measured 9 days after BTTI of 5% DMSO (black circles), 2 days (light-blue squares, dashed line), 9 days 
(dark-blue squares, solid line) after 50 mM UoS-7692 BTTI followed by furosemide/kanamycin exposure, and 2 days after furosemide/kanamycin exposure 
without BTTI (red triangles). BTTI of UoS-7692 significantly reduced threshold shifts 9 days after furosemide/kanamycin exposure for clicks and pure-tone 
frequencies of 12 and 18 kHz (1-way ANOVAs for click and individual pure-tone frequencies with Dunnett’s multiple-comparison test between the 2-day 
furosemide/kanamycin condition and the other 3 conditions). Significance levels for differences between Furos/Kana at 2 days and UoS-7692 + Furos/
Kana at 2 and 9 days are indicated by light- and dark-blue asterisks, respectively; significance levels for differences between Furos/Kana at 2 days and 
DMSO at 9 days are indicated by black asterisks. *P < 0.05; **P < 0.01; ***P < 0.001. N numbers are shown in the key. Error bars show SEM.
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good starting point for the development of  lead compounds that could alleviate the unwanted, off-target 
effects of  the otherwise clinically useful aminoglycoside antibiotics.
Methods
Chemical library
Compounds tested were from the Life Chemicals Diversity Set; 10,240 compounds were supplied pre-
dissolved and preplated at 10 mM in DMSO. Molecules effective in the initial screens were confirmed 
by testing new 10 mM stocks made from solid samples that were obtained from Life Chemicals and 
Figure 13. Structures and properties of the Diversity Set hits. Table illustrating structures and properties of the 8 com-
pounds from the Life Chemicals Diversity Set that protect mouse OHCs from exposure to gentamicin in vitro. Names of 
compounds in the first column are colored according to dendrogram group shown in Figure 1. The molecules and their 
substructure classification are based on a working model that assumes likely commonality in the mode of binding to 
the channel. Properties shown are molecular weight (MW), lipophilicity (cLogP and cLogD), calculated acid dissociation 
constant (pKa), and fractional (%) block of MET current by 50 μM of compound at a holding potential of –164 mV. The 
basic N is indicated with an asterisk. Moieties outlined are piperidine (blue), piperazine (green), benzimidazole (red), 
metachlorophenyl, pyridine (orange for UoS-5247 and UoS-962, respectively), and furan (purple). Lipophilic aromatic 
moiety for UoS-7692, UoS-8052, UoS-3607, UoS-3606, UoS-962, and UoS-9645 is outlined in magenta and lipophilic 
side chain of UoS-5247 is outlined in maroon.
1 6
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(7):e145704  https://doi.org/10.1172/jci.insight.145704
analyzed in house to confirm the structure and purity of  each compound, diluted in DMSO (Milli-
poreSigma, G3632), and divided into single-use aliquots stored at –80°C. Physicochemical properties of  
compounds were calculated using MarvinSketch 20.11 by ChemAxon (https://www.chemaxon.com).
Zebrafish neomycin and gentamicin protection assays
Zebrafish embryos were obtained from sibling crosses of  adult nacre (mifta–/–) fish (49) maintained at the 
University of  Sussex or University of  Sheffield. The rationale for using this line has been described pre-
viously (21). Larvae were maintained and all assays were performed in E3 medium (5 mM NaCl, 0.17 
mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4). In brief, larvae at 4 days dpf  were exposed to YO-PRO-1 
(Invitrogen, Y3603) to selectively prelabel the hair cells (50) and dispensed 3 to 4 per well into 96-well 
microtiter plates (Greiner). Larvae were incubated at 28°C for 1 hour in 6.25 μM neomycin sulphate 
(MilliporeSigma, N1876) in the presence of  25 μM test compound or for 6 hours in 10 μM gentamicin 
sulphate (MilliporeSigma, G3632) in the presence of  50 μM test compound. The doses of  aminogly-
cosides and the exposure times used have been previously shown to kill 75%–100% of  hair cells in 
the trunk neuromasts (21, 34). Each row of  the plate included an aminoglycoside-only control and an 
untreated control to confirm death or health of  hair cells. After washout of  compounds and aminogly-
cosides, plates were screened using a 16× 0.40 NA objective and 15× eyepieces on a Zeiss IM-35 invert-
ed microscope. Posterior lateral-line (trunk) neuromasts 3 to 9 were viewed and qualitatively assessed 
as described in Supplemental Methods. Images of  neuromast 4 were recorded with a 40× 0.75 NA 
objective using a Nikon D5000 camera.
Mouse cochlear culture preparation
Mouse cochlear cultures were prepared from wild-type CD-1 mice of  either sex as previously described 
(51). In brief, P2 pups were killed by cervical dislocation in accordance with UK Home Office guide-
lines, and heads surface-sterilized in 80% ethanol. Cochleae were removed and placed in HBSS (Gibco, 
Thermo Fisher Scientific, 14025050) buffered with 10 mM HEPES (HBHBSS; MilliporeSigma, H0887) 
for further dissection. Organs of  Corti were plated onto collagen-coated (Corning, 354236) coverslips in 
93% DMEM-F12, 7% FBS, and 10 μg/mL ampicillin (a non-ototoxic penicillin-type antibiotic), sealed 
into Maximow slide assemblies, and left to grow and adhere to the collagen for 24 hours at 37°C.
Mouse cochlear culture protection assay
After 24 hours of  incubation, coverslips with adherent cochleae were placed in 35 mm Petri dishes 
(Greiner Bio-One, 627161), and 1 mL LSM (98.8% DMEM/F12, 1.2% FBS) containing either (a) vehi-
cle (0.5% DMSO), 5 μM gentamicin in the presence of  0.5% DMSO, or 5 μM gentamicin with varying 
concentrations of  compound, or (b) either 100 µM of  protectant alone or 1% DMSO. Cultures were 
then incubated for 48 hours at 37°C. UoS-7692 was also tested at 50 μM against 20 μM tobramycin 
(MilliporeSigma, T1783) or 75 μM kanamycin (MilliporeSigma, K1377) as described above. After 48 
hours, cultures were washed in PBS, fixed at room temperature for 1 hour in 3.7% formaldehyde (v/v) 
(MilliporeSigma, F1635) in 0.1 M sodium phosphate pH 7.4, and then incubated at 4°C overnight in 
PBS containing 10% horse serum and 0.1% Triton X-100 with 1:200 Texas red phalloidin (Invitrogen, 
Thermo Fisher Scientific, T7471) and 1:1000 rabbit anti-myosin VIIa (Proteus Bio-Sciences, 25-6790), 
followed by 4 hours at room temperature in 1:500 Alexa Fluor 488 goat anti-rabbit secondary antibody 
(Invitrogen, Thermo Fisher Scientific, A-11034). Cultures were mounted in Vectashield (Vector Labo-
ratories, H-1000) and imaged using a 40× 0.75 NA objective on a Zeiss Axioplan2 upright microscope 
with a Spot RT Slider camera. Images were obtained from multiple focal planes and merged using Ado-
be Photoshop Creative Cloud. Numbers of  hair cells were counted in a 221 μm (1200 pixel) mid-basal 
region, approximately 20% along the length of  the cochlea from the basal end. OHCs were counted if  
the hair-bundle was present and if  the cell soma was not severely swollen, condensed, or fragmented.
Chemical screen data visualization
Life Chemicals Diversity compounds’ chemical structures were standardized using the Molecular Oper-
ating Environment wash procedure of  the Chemical Computing Group Inc. accessed through the Kon-
stanz Information Miner (52). Molecules were analyzed using RDKit (http://www.rdkit.org) in Python 
(https://www.python.org). Compound similarity was calculated using the Tanimoto coefficient (53) of  
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the Morgan fingerprints of  radius 2, which are equivalent to ECFP4 (54), using the scikit-learn library 
(55). A dendrogram was obtained based on all pairwise similarity values between all compounds using 
the SciPy library (http://www.scipy.org). The dendrogram and the polar scatterplot were visualized 
using the matplotlib library (56).
Electrophysiology
MET currents and basolateral potassium currents were recorded and analyzed as previously detailed 
(34). In brief, whole-cell currents were recorded from OHCs in organotypic cultures that had been pre-
pared from P2 CD-1 mice and maintained in vitro for 1 to 2 days. MET currents were recorded from 
basal-coil OHCs (to match the location of  hair cells in the protection assays) at membrane potentials 
ranging from –164 mV to +96 mV, in the absence or presence of  otoprotective compounds (50 μM). MET 
currents were also recorded during exposure to varying concentrations of  UoS-7692 (1–50 μM). Superfu-
sion of  all compounds was continued until the block appeared to reach a steady level, before superfusing 
control solution for as long as possible (up to 10 minutes) to evaluate reversibility of  the block. CsCl 
(137 mM) was included in the intracellular solution to block basolateral potassium channels. Currents 
were elicited by stimulating hair bundles using a fluid jet from a pipette (tip diameter 8–10 μm) driven 
by a piezoelectric disc (57). Mechanical stimuli (filtered at 1.0 kHz, 8-pole Bessel) were 45 Hz sinusoids 
with driver voltage amplitudes of  ±40 V. Dose-response curves of  MET current block by UoS-7692 were 
determined for all membrane potentials tested and fitted with the equation: 
(Equation 2)
where IC is control MET current, [B] is concentration of  the blocking compound, KD is half-blocking 
concentration, and nH is the Hill coefficient.
Basolateral currents were recorded at membrane potentials ranging from –154 to +46 mV in the 
absence or presence of  50 μM of  the otoprotective compounds, again taking care to reach steady-state 
block and maximizing time for the block to reverse. CsCl was substituted by KCl (131 mM) in the intra-
cellular solution. Currents were acquired using pClamp (Molecular Devices) software.
During recordings, series resistance compensation (~70%) was applied to limit the voltage drop 
across this resistance. Following compensation, the average residual series resistance was calculated to 
be 1.69 ± 0.08 MΩ (n = 58). MET currents and steady-state basolateral potassium currents reached 
maximum sizes of  1.43 ± 0.10 nA (n = 40) and 1.93 ± 0.11 nA (n = 18), respectively, resulting in voltage 
drops across the residual series resistance of  less than 5 mV, sufficiently small not to require correction to 
quoted voltage values. All experiments were conducted at 20°C–24°C.
Two-barrier 1 binding-site model of permeant MET channel block
Permeation and block of  the MET channel for compound UoS-7692 were quantified by fitting a 2-barrier 
1 binding-site model to the fractional block curves as described earlier (27, 34, 42), i.e., similar to that 
used to describe block of  the MET currents by dihydrostreptomycin (33) but modified to allow for Hill 
coefficients that differ from unity. In plotting the fractional block curves for the specific concentrations 




where Eb is the free energy of  the binding site, ΔE is the height of  the intracellular energy barrier minus the 
height of  the extracellular energy barrier, the slope factor:  is the ratio of  thermal energy (kT, i.e., 
Boltzmann’s constant multiplied by absolute temperature) and effective charge of  the blocker molecule (ze0, 
i.e., valence multiplied by elementary charge), and δb is the relative electrical distance of  the binding site 
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across the membrane, measured from the extracellular side. Fits of  the fractional block curves were opti-
mized across the range of  UoS-7692 concentrations tested using a purpose-written Python 3.0 program.
Bacterial growth conditions and antimicrobial drug susceptibility assay
Bacterial growth and antimicrobial susceptibility screens were performed as described previously (21). Brief-
ly, Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa were passaged twice on Luria- 
Bertani agar from frozen stocks and cultured in Mueller Hinton Broth at 37°C with shaking at 200 RPM. The 
minimum inhibitory concentration (MIC) of  gentamicin was determined by microbroth dilution method to 
be 2.2 μM for all 3 strains. To test whether UoS-7692 abrogated the antimicrobial efficacy of  gentamicin, 
bacteria (3–5 × 105 CFU/mL) were exposed to a 1:5 mixture of  gentamicin and UoS-7692 (MIC gentamicin 
[2.2 μM]/UoS-7692) and incubated at 37°C for 16–20 hours. Bacterial ATP was quantified as a measure of  
viability using the BacTiter-Glo Microbial Cell Viability Assay (Promega) according to the manufacturer’s 
instructions. The experiment was repeated in triplicate.
GTTR loading assay
Loading of  GTTR (a gift from Peter Steyger, Creighton University School of  Medicine, Omaha, Nebraska, 
USA) was assayed as described previously (21). In brief, 1-day old cochlear cultures prepared from P2 mice 
were incubated in 0.1% DMSO or 100 μM UoS-7692 in HBHBSS for 5 minutes, and GTTR was added 
to a final concentration of  0.2 μM for a further 10 minutes. Cultures were washed 3 times with HBHBSS, 
placed in a viewing chamber with fresh HBHBSS, and GTTR fluorescence was recorded with a 63× 0.90 
NA water immersion lens on a Zeiss Axioplan2 upright microscope with a Spot RT Slider camera. Images 
were collected at a fixed distance from the basal end of  the culture 10 minutes after the onset of  GTTR 
washout. Experiments were performed at 22°C to 24°C and on 3 independent occasions. For each culture, 
intensity values were obtained from 40 × 40 pixel ROIs from 10 consecutive OHCs in a row and 4 back-
ground regions. The average of  the background fluorescence values was subtracted from each individual 
OHC value to give the final intensity value for each OHC.
Measurements of motility in zebrafish larvae
Zebrafish larvae (5 dpf) were treated with E3, E3 containing 6.25 μM neomycin, or E3 containing 25 μM 
UoS-7692 and 6.25 μM neomycin for 1 hour, washed 3 times with E3 media, and 12 fish from each treatment 
group were then dispensed into individual wells of  a 48-well plate in 1 mL of E3. Larvae were left for 30 min-
utes at 28°C to acclimatize to the wells before larval movement was tracked in the light using a Noldus Danio-
vision Observation Chamber over a 30-minute period. After tracking, 3 larvae from each treatment group 
were labeled with 3 μM of YO-PRO-1 for 15 minutes and assessed on a Zeiss IM35 inverted microscope as 
described above. Experiments were repeated on 3 independent occasions.
To ensure treatment with compound UoS-7692 alone does not alter the behavior of the larvae, 5 dpf zebraf-
ish were treated with either E3 medium or 25 μM UoS-7692 in E3 for 1 hour. After washing with E3, 16 fish from 
each treatment group were dispensed into individual wells of a 48-well plate and assayed as described above.
TTI of UoS-7692 into the mouse middle ear
Compounds were delivered into the middle ear by TTI using a microinjection system (Ultramicropump 3, 
WPI). The pump was linked by narrow bore tubing to a handheld 33G beveled needle. Estimates suggest that 
a 2 to 3 order of  magnitude drop in concentration of  compound occurs between the middle and inner ear as a 
result of  limited permeability of  the window membranes (58). UoS-7692 was therefore used at 50 mM (to give 
an estimated endolymphatic concentration of  50–500 μM), and was diluted in water containing 5% DMSO to 
improve round-window permeability (58).
Mice were anesthetized with an i.p. injection of  10 μL/g ketamine/xylazine anesthetic (10 mg/mL ket-
amine hydrochloride, 1 mg/mL xylazine hydrochloride in water), then positioned on their side for viewing of  
the desired ear canal. Two holes were made in the tympanum with the needle, 1 posterior and 1 anterior to the 
incus handle, and 4 to 5 μL of compound was delivered through the anterior hole. After TTI, each mouse was 
maintained on its side for 20 minutes before i.p. injection of  4 μL/g of  xylazine recovery agent (atipamezole 
hydrochloride 0.25 mg/mL, Pfizer). Each mouse was placed in a recovery cage and monitored until active 
(~25–40 minutes after atipamezole). For injections in both ears, the mouse was turned on its reverse side after 
20 minutes, and the process repeated on the second ear.
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Aminoglycoside treatment of TTI mice
Four hours (+/– 1 hour) after TTI, mice were given an i.p. injection of  15 μL/g furosemide (10 mg/mL 
stock). Kanamycin (100 mM kanamycin A sulphate [MilliporeSigma, K1876] in HBHBSS) was injected 30 
minutes later at 5 μL/g (males) or 3 to 4 μL/g (females) by the i.p. route (doses found to consistently induce 
comparable hearing loss and OHC toxicity), on the opposite side of  the body to the furosemide injection. 
Mice were housed separately, their diet supplemented with wet mash, and monitored twice daily until ABR 
assessment, either 2 or 9 days later. Saline injections were given if  weight dropped by more than 10% of  
starting value. No mice showed observable ill effects and all regained normal weight within 2 days.
ABR measurements
ABR methods were carried out following established procedures (59) using Tucker-Davis Technologies 
equipment. Heart rate, 70 dB click-evoked ABR, click-evoked ABR level series (20–95 dB), and tone-
evoked ABRs (20–95 dB) at 12–36 kHz were carried out with free-field stimuli for all mice at either 2 or 
9 days after injection (TTI and/or furosemide/kanamycin). When a waveform was not present at 95 dB, 
the highest level tested, response threshold was recorded as 100 dB for analysis purposes. Threshold shifts 
were measured relative to average levels required to elicit a detectable response in a cohort of  mice (n = 
5) 2 days after a single injection of  furosemide alone (150 μg/g), a procedure that does not cause hearing 
loss (Supplemental Figure 3).
Assessment of cochlear morphology
After ABR measurements, mice were overdosed with anesthetic (0.25 mL of  pentobarbital; Vetoquinol). 
The head was removed after death and bisected, the labyrinths extracted, and the round and oval windows 
were opened. Cochleae were immersion-fixed (3.7% formaldehyde [v/v], 0.1 M sodium phosphate, pH 7.4) 
at 4°C overnight. Cochleae were washed 3 times in PBS and decalcified in 0.5 M EDTA pH 8.0, for 3–4 
days at 4oC, with active agitation. Once decalcified, each cochlea was washed in PBS and sliced into 4 piec-
es, and the organ of  Corti was dissected from each piece using iterative trimming as previously described 
(60). Pieces were preblocked for 1 hour in PBS containing 10% horse serum and 0.1% Triton X-100 and 
incubated overnight at 4oC in 1:1000 goat anti-prestin antibody (Santa Cruz Biotechnology, sc-22692) 
and 1:2000 Atto-488 phalloidin (MilliporeSigma, 49409) diluted in preblock. After 3 PBS washes, pieces 
were incubated in Alexa Fluor 586 donkey anti–goat IgG for 4 hours (Thermo Fisher Scientific, A-11057), 
washed, and mounted under glass coverslips in Vectashield.
Cochleae were photographed at 10× on a Zeiss AxioPlan2 microscope with a Jenoptik Gryphax Arktur 
camera, and photomontages of  cochleae were generated in Adobe Photoshop CC. Using ImageJ (NIH), 
the entire length of  the cochlear coil was measured, and points 20%, 40%, 60%, and 80% from the apex 
were marked. Super-resolution images of  hair cells were captured from these regions using an Airyscan 
Zeiss 880 LSM and 63× 1.4 NA oil-immersion objective. Z-projections were created in Zeiss LSM Browser 
4.2 software using the keep maximum transparency function; threshold, ramp, maximum opacity, and 
brightness were adjusted to prevent the signal from the cuticular plate from obscuring the hair-bundles. 
Subsequent images were captured in wide field with a 63× 1.4 NA oil-immersion lens on a Zeiss AxioPlan2 
microscope as described above to quantify hair-cell survival at intervals 40%, 60%, and 80% from the 
cochlear apex. Comparable levels of  hair-cell loss were seen in both left and right ears in all mice observed 
that did not receive otoprotectant. Occasionally, mice that received kanamycin treatment did not show hair-
cell loss in nonprotected cochleae, and these mice were excluded from the study to avoid false positives.
Statistics
Mouse cochlear culture protection assay. OHC survival was compared by 1-way ANOVA with Tukey’s mul-
tiple-comparison test between control cultures, cultures treated with aminoglycosides alone, and cultures 
treated with aminoglycosides and test compounds. Statistical analysis was performed using GraphPad 
Prism version 8.0. P values less than 0.05 were considered significant.
Electrophysiology. Where currents recorded from multiple cells were averaged, means ± SEM are quoted 
and shown in figures. Values for fitting parameters in dose-response and fractional block curves are report-
ed as means with 95% CI.
Bacterial growth conditions and antimicrobial drug susceptibility testing. Assays were analyzed using linear 
mixed effects models, modeling the multiple variance components in the hierarchical experimental design 
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(61–63). Each assay (Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa) was analyzed 
separately. Natural logarithm-transformed luminescence was used as the response variable. Compound iden-
tity (including compound-free control) was fitted as a single categorical explanatory variable, and pairwise 
contrasts were assessed, comparing each compound with the control. Technical replication, nested within 
biological variation, was fitted as random effects, with Gaussian errors. Analysis was performed using the R 
statistical programming environment, version 3.3.1 (64).
GTTR loading assay. Background-corrected fluorescence values in hair cells treated with GTTR, with 
and without prior incubation with UoS-7692, were analyzed by a 2-tailed t test. Statistical analysis was 
performed using GraphPad Prism version 8.0.
Measurements of  motility in zebrafish larvae. The natural logarithm of  the distance traveled over a 1-minute 
sample window was plotted. Since the data set included some distances of  0 mm, data + 1 was used to avoid 
ln(0) values in the analysis. A Kruskal-Wallis rank-sum test was used to analyze differences between the 
distance traveled in E3 medium alone, E3 medium with neomycin, and E3 medium with both UoS-7692 and 
neomycin; pairwise comparisons were made using Dunn’s post hoc test. A 2-sample, 2-tailed t test was used 
to analyze the differences between the distances traveled in E3 medium and E3 medium containing UoS-
7692. Plots and statistical analysis were conducted in R, version 3.5.0 (64).
In vivo hair-cell survival and ABR threshold shifts. OHC survival in the cochleae of  mice that received 
systemic injection with furosemide/kanamycin and single ear TTI of  UoS-7692 or DMSO was analyzed 
by 2-way ANOVA with matched pairs design between cochleae from the same animal, followed by Šidák’s 
multiple-comparison test between injected and noninjected ears.
ABR threshold shifts from baseline were analyzed by 1-way ANOVA for click and individual pure-tone 
frequencies with Dunnett’s multiple-comparison test between each condition and either the 9-day DMSO 
condition or the 2-day kanamycin/furosemide-alone condition. Statistical analysis was performed using 
GraphPad Prism version 8.0.
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